{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:34:45Z","timestamp":1768631685157,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T00:00:00Z","timestamp":1410307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary mediastinal B\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">PMBL<\/jats:styled-content>) is a subtype of diffuse large B\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>) that arises in the mediastinum from B\u2010cells of thymic origin. Optimal management of patients with <jats:styled-content style=\"fixed-case\">PMBL<\/jats:styled-content> remains controversial. The present study evaluates outcomes of 27 <jats:styled-content style=\"fixed-case\">PMBL<\/jats:styled-content> patients treated with R\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> with or without radiation therapy (<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>). It investigates the role of both interim and posttreatment fluorodeoxyglucose\u2010positron emission tomography (<jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>) as prognostic markers of outcome. Additionally, it assesses postprogression therapies in the six patients who had progressive disease. At a median follow\u2010up of 41.5\u00a0months (range: 6.1\u2013147.2\u00a0months), <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 95.5% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\u00a0=\u00a071.9\u201399.4) and progression\u2010free survival (PFS) was 70.4% (95% CI\u00a0=\u00a049.4\u201383.9) for the entire cohort. The negative predictive values of interim and posttreatment <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> scans were both 100%. Patients who failed initial therapy and were treated with salvage regimens and autologous stem cell transplantation (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>) all achieved and maintained <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">PMBL<\/jats:styled-content> patients can achieve excellent outcomes with minimal toxicities when treated with R\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> with or without <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>. Negative interim and negative posttreatment <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> results identified <jats:styled-content style=\"fixed-case\">PMBL<\/jats:styled-content> patients who achieve long\u2010term remission. However, the significance of both positive interim and positive posttreatment <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> results needs to be better defined. Those who failed initial therapy were successfully treated with salvage regimens and <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>.<\/jats:p>","DOI":"10.1002\/cam4.322","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T10:26:55Z","timestamp":1410344815000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The role of <scp>FDG<\/scp>\u2010<scp>PET<\/scp> imaging as a prognostic marker of outcome in primary mediastinal B\u2010cell lymphoma"],"prefix":"10.1002","volume":"4","author":[{"given":"Sarah J.","family":"Nagle","sequence":"first","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seble","family":"Chekol","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Glatstein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew A.","family":"Torigian","sequence":"additional","affiliation":[{"name":"Department of Radiology University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.349"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05661.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0275"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.784"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.904"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf256"},{"key":"e_1_2_8_9_1","first-page":"4464","article-title":"Positron emission tomography in non\u2010Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose","volume":"91","author":"Romer W.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.9298"},{"key":"e_1_2_8_11_1","first-page":"1018","article-title":"PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease","volume":"43","author":"Kostakoglu L.","year":"2002","journal-title":"J. Nucl. Med."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25579"},{"key":"e_1_2_8_13_1","first-page":"522","article-title":"18F\u2010fluoro\u2010deoxyglucose positron emission tomography for post\u2010treatment evaluation of malignant lymphoma: a systematic review","volume":"91","author":"Zijlstra J. M.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.414"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2930"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03147.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.2.429"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2305"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_20_1","unstructured":"National Cancer Institute.2009.Common terminology criteria for adverse events v4.0 NIH publication # 09\u20107473."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj030"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0536-6"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22276"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.2648"},{"key":"e_1_2_8_26_1","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings M.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602040"},{"key":"e_1_2_8_28_1","first-page":"1769","article-title":"Role of positron emission tomography (PET\/CT) in primary mediastinal large B cell lymphoma (PMLBCL): preliminary results of an international phase II trial (IELSG\u201026 study) conducted on behalf of the International Extranodal Lymphoma Study Group (IELSG), the fondazione italiana linfomi (FIL) and the UK NCRI lymphoma group","volume":"32","author":"Ceriani L.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5942"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.397.3798512"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.322","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.322","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:52:40Z","timestamp":1696539160000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1002\/cam4.322"],"URL":"https:\/\/doi.org\/10.1002\/cam4.322","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,10]]},"assertion":[{"value":"2014-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}